MannKind Corporation

NasdaqGM:MNKD Stock Report

Market Cap: US$1.6b

MannKind Future Growth

Future criteria checks 4/6

MannKind is forecast to grow earnings and revenue by 39.7% and 13.9% per annum respectively while EPS is expected to grow by 38.7% per annum.

Key information

39.7%

Earnings growth rate

38.7%

EPS growth rate

Biotechs earnings growth27.7%
Revenue growth rate13.9%
Future return on equityn/a
Analyst coverage

Low

Last updated18 Dec 2024

Recent future growth updates

Recent updates

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Dec 17

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Oct 03

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

Jul 17
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

MannKind Outperforms As Tyvaso DPI Captures Market Share

May 15

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 02
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

Feb 15

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Jan 03
MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

May 15
Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Jan 27
MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19
New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

Aug 09

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

Feb 25

MannKind: A Promising Player In The Inhalable Insulin Market

Feb 08

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14
US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Lytham Partners Summer 2021 Investor Conference

Jun 14

MannKind (MNKD) Investor Presentation - Slideshow

Jun 04

MannKind reduces debt by $49.5M and restructures remaining obligations

Apr 26

Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Feb 22
Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

MannKind to co-promote Thyquidity

Dec 17

Earnings and Revenue Growth Forecasts

NasdaqGM:MNKD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026385102157714
12/31/202533263122614
12/31/20242842894374
9/30/2024267222942N/A
6/30/2024248121841N/A
3/31/20242258340N/A
12/31/2023199-12-834N/A
9/30/2023177-31-3210N/A
6/30/2023158-47-57-27N/A
3/31/2023128-71-72-61N/A
12/31/2022100-87-88-81N/A
9/30/202276-98-98-91N/A
6/30/202266-88-89-78N/A
3/31/202270-94-83-67N/A
12/31/202175-81-73-62N/A
9/30/202181-79-60-49N/A
6/30/202175-86-54-47N/A
3/31/202166-61-35-30N/A
12/31/202065-57-33-28N/A
9/30/202063-45-34-33N/A
6/30/202062-44-73-72N/A
3/31/202062-46-91-88N/A
12/31/201963-52-91-88N/A
9/30/201963-47-61-58N/A
6/30/201953-61-22-20N/A
3/31/201942-71-28-28N/A
12/31/201828-87-38-38N/A
9/30/201816-110-93-93N/A
6/30/201813-119N/A-102N/A
3/31/201812-131N/A-95N/A
12/31/201711-117N/A-65N/A
9/30/201720-31N/A-48N/A
6/30/2017180129N/A-47N/A
3/31/2017178134N/A-39N/A
12/31/2016175126N/A-78N/A
9/30/2016162-205N/A-88N/A
6/30/2016N/A-364N/A-85N/A
3/31/2016N/A-363N/A-91N/A
12/31/2015N/A-368N/A-57N/A
9/30/2015N/A-128N/A-70N/A
6/30/2015N/A-133N/A50N/A
3/31/2015N/A-177N/A44N/A
12/31/2014N/A-198N/A4N/A
9/30/2014N/A-216N/A6N/A
6/30/2014N/A-230N/A-127N/A
3/31/2014N/A-203N/A-134N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MNKD's forecast earnings growth (39.7% per year) is above the savings rate (2.6%).

Earnings vs Market: MNKD's earnings (39.7% per year) are forecast to grow faster than the US market (15.3% per year).

High Growth Earnings: MNKD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MNKD's revenue (13.9% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: MNKD's revenue (13.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MNKD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 00:53
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MannKind Corporation is covered by 26 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas RussoBaird
Stephen V. ByrneBofA Global Research
null nullBTIG